- Publisher Correction: Cell types of origin of the cell-free transcriptome. Nature biotechnology 2022
Cell types of origin of the cell-free transcriptome.
Cell-free RNA from liquid biopsies can be analyzed to determine disease tissue of origin. We extend this concept to identify cell types of origin using the Tabula Sapiens transcriptomic cell atlas as well as individual tissue transcriptomic cell atlases in combination with the Human Protein Atlas RNA consensus dataset. We define cell type signature scores, which allow the inference of cell types that contribute to cell-free RNA for a variety of diseases.
View details for DOI 10.1038/s41587-021-01188-9
View details for PubMedID 35132263
- RNA splicing programs define tissue compartments and cell types at single-cell resolution ELIFE 2021; 10
Hesperetin Liposomes for Cancer Therapy.
Current drug delivery
2016; 13 (5): 711-9
Hesperetin is a compound from citrus fruit that has previously been found to exert anticancer activity through a variety of mechanisms. However, the application of hesperetin to cancer therapy has been hampered by its hydrophobicity, necessitating the use of toxic solubilizing agents. Here, we have developed the first liposome-based delivery system for hesperetin. Liposomes were fabricated using the thin-layer evaporation technique and physical and pharmacological parameters were measured. The liposomes remained stable for prolonged periods of time in serum and under storage conditions, and displayed anticancer efficacy in both H441 lung cancer cells and MDA-MB-231 breast cancer cells. Furthermore, the anticancer activity was not impaired in cells expressing the multidrug resistance protein 1 (MDR-1). In conclusion, the encapsulation of hesperetin in liposomes does not interfere with therapeutic efficacy and provides a biocompatible alternative to toxic solubilizing agents, thereby enabling future clinical use of this compound for cancer therapy.
View details for DOI 10.2174/1567201812666151027142412
View details for PubMedID 26502889
View details for PubMedCentralID PMC6677249
A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.
2016; 111: 413-421
Cancer cells have high rates of glycolysis and lactic acid fermentation in order to fuel accelerated rates of cell division (Warburg effect). Here, we present a strategy for merging cancer and yeast metabolism to remove pyruvate, a key intermediate of cancer cell metabolism, and produce the toxic compound acetaldehyde. This approach was achieved by administering the yeast enzyme pyruvate decarboxylase to triple negative breast cancer cells. To overcome the challenges of protein delivery, a nanoparticle-based system consisting of cationic lipids and porous silicon were employed to obtain efficient intracellular uptake. The results demonstrate that the enzyme therapy decreases cancer cell viability through production of acetaldehyde and reduction of lactic acid fermentation.
View details for DOI 10.1016/j.phrs.2016.07.005
View details for PubMedID 27394167
View details for PubMedCentralID PMC5026593
Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells.
Journal of microencapsulation
2014; 31 (5): 501-7
Celastrol, a natural compound derived from the herb Tripterygium wilfordii, is known to have anticancer activity, but is not soluble in water.Formation of celastrol liposomes, to avoid the use of toxic solubilising agents.Two different formulations of PEGylated celastrol liposomes were fabricated. Liposomal characteristics and serum stability were determined using dynamic light scattering. Drug entrapment efficacy and drug release were measured spectrophotometrically. Cellular internalisation and anticancer activity was measured in prostate cancer cells.Liposomal celastrol displayed efficient serum stability, cellular internalisation and anticancer activity, comparable to that of the free drug reconstituted in dimethyl sulfoxide.Liposomal celastrol can decrease the viability of prostate cancer cells, while eliminating the need for toxic solubilising agents.
View details for DOI 10.3109/02652048.2013.879932
View details for PubMedID 24654943
View details for PubMedCentralID PMC4230278